Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q1 FY27 consolidated sales grew 10.1% y-y to INR151,836 million; EBITDA margin 28.9% - Innovative medicines sales up 12.8% to USD351 million; driven by ILUMYA, ODOMZO, CEQUA - India formulations sales grew 16%, market share increased to 8.5%; volume growth 5.4% - US sales declined 9.7% due to generic erosion; innovative portfolio growing with Leqselvi and Unloxcyt - Emerging markets sales up 4.2%; Rest of World flat at USD218 million - R&D spend at 5.4% of sales; 30% on innovative medicines; Organon acquisition on track for Q4 FY27 - Management expects high single-digit revenue growth for FY27; tax rate around 27.8% - Multiple analyst queries on specialty product ramp-up and US generics outlook; management expects sustained growth but no product-wise guidance